keyword
MENU ▼
Read by QxMD icon Read
search

adjuvant therapy breast cancer

keyword
https://www.readbyqxmd.com/read/29776011/predicting-nonadherence-to-adjuvant-endocrine-therapy-in-women-with-early-stage-breast-cancer
#1
Arden L Corter, Reuben Broom, David Porter, Vernon Harvey, Michael Findlay
BACKGROUND: Failing to take endocrine therapy (ET) as prescribed (nonadherence) increases risk of morbidity and mortality from breast cancer recurrence. We explored predictors of nonadherence, including demographic, clinical, treatment and personal factors, among women newly prescribed ET for early stage breast cancer. We also examined predictors of their thoughts about stopping treatment (TST). METHODS: A baseline survey prior to ET assessed demographics, illness beliefs, beliefs about medicines, fear of recurrence, symptoms and negative affect...
May 18, 2018: Psycho-oncology
https://www.readbyqxmd.com/read/29773838/impact-of-timing-of-trastuzumab-initiation-on-long-term-outcome-of-patients-with-early-stage-her2-positive-breast-cancer-the-one-thousand-her2-patients-project
#2
Giuseppe Gullo, Naomi Walsh, David Fennelly, Reetesh Bose, Janice Walshe, Dimitrios Tryfonopoulos, Kate O'Mahony, Lisa Hammond, Nuno Silva, Deirdre McDonnell, Josephine Ballot, Cecily Quinn, Enda W McDermott, Denis Evoy, Ruth Prichard, James Geraghty, John Amstrong, John Crown
BACKGROUND: The optimal timing of (neo)adjuvant trastuzumab initiation with respect to chemotherapy and surgery remains undefined. METHODS: Retrospective analysis of a large institutional database of HER2-positive patients who received anti-HER2 therapy. We included all Stage I to III patients treated with trastuzumab with a minimum follow up of 3 years. The date of first breast biopsy was recorded as initial diagnosis. RESULTS: A total of 506 patients [adjuvant: 386 (76%)-neo-adjuvant: 120 (24%)] were included...
May 18, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29770955/laptm4b-gene-copy-number-gain-is-associated-with-inferior-response-to-anthracycline-based-chemotherapy-in-hormone-receptor-negative-breast-carcinomas
#3
Orsolya Rusz, Orsolya Papp, Laura Vízkeleti, Béla Ákos Molnár, Kristóf Csaba Bende, Gábor Lotz, Balázs Ács, Zsuzsanna Kahán, Tamás Székely, Ágnes Báthori, Csilla Szundi, Janina Kulka, Zoltán Szállási, Anna-Mária Tőkés
PURPOSE: To determine the associations between lysosomal-associated transmembrane protein 4b (LAPTM4B) gene copy number and response to different chemotherapy regimens in hormone receptor negative (HR-) primary breast carcinomas. PATIENTS AND METHODS: Two cohorts were analyzed: (1) 69 core biopsies from HR-breast carcinomas treated with neoadjuvant chemotherapy (anthracycline based in 72.5% of patients and non-anthracycline based in 27.5% of patients). (2) Tissue microarray (TMA) of 74 HR-breast carcinomas treated with adjuvant therapy (77...
May 16, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29770779/effect-of-neoadjuvant-chemotherapy-on-the-expression-of-hormone-receptors-and-ki-67-in-chinese-breast-cancer-patients-a-retrospective-study-of-525-patients
#4
Yu-Tuan Wu, Xin Li, Lin-Jie Lu, Lu Gan, Wei Dai, Yan-Ling Shi, Vishnu Prasad Adhikari, Kai-Nan Wu, Ling-Quan Kong
This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and ki67 in Chinese female breast cancer patients. The expression of estrogen receptor (ER), progesterone receptor (PR) and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry (IHC). Differences between specimens made through preoperative core needle biopsy (CB) and excised tissue biopsy (EB) were observed. The positive rates of ER, PR and Ki67 in CB and EB were 65...
November 1, 2017: Journal of Biomedical Research
https://www.readbyqxmd.com/read/29769099/circulating-esr1-mutations-at-the-end-of-aromatase-inhibitor-adjuvant-treatment-and-after-relapse-in-breast-cancer-patients
#5
Violette Allouchery, Ludivine Beaussire, Anne Perdrix, David Sefrioui, Laetitia Augusto, Cécile Guillemet, Nasrin Sarafan-Vasseur, Frédéric Di Fiore, Florian Clatot
BACKGROUND: Detection of circulating ESR1 mutations is associated with acquired resistance to aromatase inhibitor (AI) in metastatic breast cancer. Until now, the presence of circulating ESR1 mutations at the end of adjuvant treatment by AI in early breast cancer had never been clearly established. In this context, the aim of the present study was to evaluate the circulating ESR1 mutation frequency at the end of adjuvant treatment and after relapse. METHODS: This monocentric retrospective study was based on available stored plasmas and included all early breast cancer patients who completed at least 2 years of AI adjuvant treatment and experienced a documented relapse after the end of their treatment...
May 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29766362/exploration-of-tumour-infiltrating-lymphocytes-as-a-predictive-biomarker-for-adjuvant-endocrine-therapy-in-early-breast-cancer
#6
Erik J Blok, Charla C Engels, Geeske Dekker-Ensink, Elma Meershoek-Klein Kranenbarg, Hein Putter, Vincent T H B M Smit, Gerrit-Jan Liefers, James P Morden, Judith M Bliss, R Charles Coombes, John M S Bartlett, Judith R Kroep, Cornelis J H van de Velde, Peter J K Kuppen
PURPOSE: Tumour-infiltrating lymphocytes (TILs) have been shown to be prognostic for disease-free survival and predictive for the benefit of chemotherapy in patients with early breast cancer, but have not been studied for endocrine therapy. EXPERIMENTAL DESIGN: The number of CD8-positive TILs was assessed in a subcohort of 236 patients in the Intergroup Exemestane Study. AQ After 2-3 years of adjuvant tamoxifen, AQpatients were randomized between the schemes of continuation for 5 years on tamoxifen and switching to exemestane...
May 15, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29759595/her2-positive-lobular-versus-ductal-carcinoma-of-the-breast-pattern-of-first-recurrence-and-molecular-insights
#7
Lucia Da Ros, Anna Moretti, Patrizia Querzoli, Massimo Pedriali, Laura Lupini, Cristian Bassi, Paolo Carcoforo, Massimo Negrini, Antonio Frassoldati
BACKGROUND: Infiltrating lobular carcinoma (ILC) represents about 10% of breast cancer and rarely shows overexpression of human epidermal growth factor receptor 2 (HER2). We compared biological and clinical characteristics of HER2-positive ILC versus HER2-positive infiltrating ductal carcinoma (IDC). PATIENTS AND METHODS: We retrospectively analyzed the data of 328 patients with HER2-positive pure ductal or lobular breast carcinoma, comparing clinical and biological data at diagnosis as well as outcome between the 2 histologies...
April 18, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29756115/severe-decrease-in-spo-2-and-methemoglobinemia-following-subareolar-isosulfan-blue-administration-and-clinical-relevance
#8
Esra Yüksel, Dilek Duman, Levent Yeniay, Sezgin Ulukaya
The level of axillary lymph node involvement in breast cancer is a critical decision factor for adjuvant therapy and the most important indicator of prognosis and survival. Sentinel lymph node biopsy is a minimally invasive technique with low morbidity in axillary staging of breast cancer. Radiocolloid substances (Technetium-99m) and/or blue dyes such as methylene blue or isosulfan blue are used during sentinel lymph node biopsy. Isosulfan blue stain is frequently used in sentinel lymph node biopsy and rarely causes complications...
2018: Turkish Journal of Surgery
https://www.readbyqxmd.com/read/29755905/a-case-of-neurotrophic-keratopathy-concomitant-to-brain-metastasis
#9
Chiara Bonzano, Elisabetta Bonzano, Carlo Alberto Cutolo, Riccardo Scotto, Carlo Enrico Traverso
We report a case of a 63-year-old Caucasian female referred to the cornea service of Clinica Oculistica with a neurotrophic corneal ulcer, decreased corneal sensitivity, absent corneal reflex, and decreased lacrimation. The medical record review was relevant for mastectomy and adjuvant therapy for breast cancer complicated by pontocerebellar angle metastasis. Eye patching and application of antibiotic and vitamin ointments were prescribed at first, without a significant improvement. Thus, treatment with autologous serum was started...
March 12, 2018: Curēus
https://www.readbyqxmd.com/read/29754304/impact-of-high-deductible-insurance-on-adjuvant-hormonal-therapy-use-in-breast-cancer
#10
Christine Y Lu, Fang Zhang, Anita K Wagner, Larissa Nekhlyudov, Craig C Earle, Matthew Callahan, Robert LeCates, Xin Xu, Dennis Ross-Degnan, J Frank Wharam
OBJECTIVE: High-deductible health plans (HDHPs) have become the predominant commercial health insurance arrangement in the US. HDHPs require substantial out-of-pocket (OOP) costs for most services but often exempt medications from high cost sharing. We examined effects of HDHPs on OOP costs and utilization of adjuvant hormonal therapy (AHT), which are fundamental care for patients with breast cancer. METHODS: This controlled quasi-experimental study used claims data (2003-2012) from a large national health insurer...
May 12, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29753961/the-role-of-parp-inhibition-in-triple-negative-breast-cancer-unraveling-the-wide-spectrum-of-synthetic-lethality
#11
REVIEW
Marios Papadimitriou, Giannis Mountzios, Christos A Papadimitriou
Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast cancers and is characterized by a lack of immunohistochemical expression of estrogen receptors (ER), progesterone receptors (PR) and HER2. TNBC is associated with poor long-term outcomes compared with other breast cancer subtypes. Many of these tumors are also basal-like cancers which are characterized by an aggressive biological behavior with a distant recurrence peak observed early at 3 years following diagnosis. Furthermore, metastatic TNBC bears a dismal prognosis with an average survival of 12 months...
May 2, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29752333/the-endocrinology-of-male-breast-cancer
#12
REVIEW
Ian S Fentiman
Male breast cancer (MBC) is a rare disease but, as a result of epidemiological collaborations, there is now greater clarity concerning endocrine risk factors. The significant rise in global age-standardised mean BMI in men is likely to lead to increases in incidence of maturity-onset diabetes and MBC. The metabolic changes accompanying obesity decrease androgens and sex hormone-binding globulin (SHBG), thereby increasing available oestrogens. The higher rates of MBC in North and Equatorial Africa are largely due to liver damage from endemic bilharziasis and hepatitis B causing elevated oestradiol (E2 ) levels from hepatic conversion of androgen...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29748884/predictors-of-residual-disease-after-breast-conservation-surgery
#13
Lisa J Findlay-Shirras, Oussama Outbih, Charlene N Muzyka, Katie Galloway, Pamela C Hebbard, Maged Nashed
INTRODUCTION: Breast-conserving therapy is the standard of care for early-stage breast cancer. In the era of multimodality therapy, the debate on the value of revision surgery for compromised margins continues, and high re-excision rates persist despite updated guidelines. Our study sought to identify the local re-excision rate for compromised margins after lumpectomy, and identify predictors of residual disease at re-excision. METHODS: This population-based retrospective cohort study included women with breast cancer who underwent a lumpectomy between 2009 and 2012 in Manitoba, with close (≤ 2 mm) or positive margins that led to re-excision...
May 10, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29745102/serbian-consensus-of-neoadjuvant-therapy-for-breast-cancer-neopulse
#14
Lazar Popovic, Zorica Tomasevic, Ljiljana Stamatovic, Ivan Markovic, Gorana Matovina-Brko, Marko Buta, Andrija Golubovic, Vladimir Selakovic, Jasna Trifunovic, Zafir Mutrezani, Nebojsa Ivanovic, Jasmina Nedovic, Srdjan Ninkovic, Sladjana Filipovic, Ana Cvetanovic, Nebojsa Djordjevic, Aleksandar Karanikolic, Tatjana Ivkovic-Kapic, Ferenc Vicko
Even though surgery is the primary treatment of operable breast cancer, it has been known for decades that the administration of postoperative adjuvant or preoperative neoadjuvant therapy is extremely important. Indications for neodjuvant therapy administration have been expanded over the years, and nowadays this kind of treatment represents an inevitable option in early breast cancer treatment. The NeoPULSE project, which gathered a group of experts in the field of breast cancer from five Serbian university centres, was formed with the aim to define optimal breast cancer diagnosis, indications for neoadjuvant therapy, therapeutic combinations in relation to molecular/biological parameters of breast cancer, as well as the treatment after neoadjuvant therapy...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29745076/ten-years-of-using-adjuvant-trastuzumab-in-breast-cancer-in-serbia-single-institution-experience
#15
Ana Cvetanovic, Sladjana Filipovic, Nikola Zivkovic, Lazar Popovic, Milos Kostic, Miodrag Djordjevic, Aleksandar Karanikolic, Dane Krtinic
PURPOSE: The purpose of this study was to determinate disease-free interval (DFI) and overall survival (OS) in HER2-positive breast cancer patients who received adjuvant trastuzumab at the University Clinic of Nis, Serbia, and to investigate the influence of clinicopathological and biological characteristics of the tumor on prognosis. The second aim was to determinate the most frequent cause for the treatment discontinuation, recurrence rate, as well as the site of most common localization of the first recurrence of disease...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29744328/bilateral-metachronous-breast-carcinoma-a-rare-case-report
#16
Anand Singla, Navneet Kaur, Darshanjeet Singh Walia, Deeksha Singla
The occurrence of bilateral breast cancer is rare. A second primary in the contralateral breast can either be synchronous or metachronous. Lobular carcinoma of the breast is known for its multicentricity and bilateral spread. The synchronous mixed pattern of carcinoma of the breast has also been reported in the same breast. The family history of breast carcinoma, estrogen receptor negativity, and human epidermal growth factor receptor-2 positivity are risk factors for the development of contralateral breast malignancy...
April 2018: International Journal of Applied and Basic Medical Research
https://www.readbyqxmd.com/read/29741296/assessment-and-management-of-bone-health-in-women-with-oestrogen-receptor-positive-breast-cancer-receiving-endocrine-therapy-position-statement-of-the-endocrine-society-of-australia-the-australian-and-new-zealand-bone-mineral-society-the-australasian-menopause
#17
Mathis Grossmann, Sabashini Ramchand, Frances Milat, Amanda Vincent, Elgene Lim, Mark A Kotowicz, Jill Hicks, Helena Teede
OBJECTIVE: To formulate clinical consensus recommendations on bone health assessment and management of women with oestrogen receptor-positive early breast cancer receiving endocrine therapy. METHODS: Representatives appointed by relevant Australian Medical Societies used a systematic approach for adaptation of guidelines (ADAPTE) to derive an evidence-informed position statement addressing five key questions. RESULTS: Women receiving adjuvant aromatase inhibitors and the subset of premenopausal woman on tamoxifen have accelerated bone loss and increased fracture risk...
May 9, 2018: Clinical Endocrinology
https://www.readbyqxmd.com/read/29739815/impact-of-hormone-receptor-status-on-the-efficacy-of-her2-targeted-treatment
#18
Bin Zhao, Hong Zhao, Jiaxin Zhao
The introduction of human epidermal growth factor receptor 2 (HER2)-targeted drugs into routine clinical practice has a dramatic effect on the outlook for patients with HER2-positive breast cancer (BC). However, the association between efficacy of HER2-targeted therapy and hormone receptor (HR) status is still unclear. Here we conducted a meta-analysis of randomized controlled trials (RCTs) to address this issue in both neoadjuvant and adjuvant settings. PubMed and EMBASE were searched from inception to October 2017 for studies involving trastuzumab, lapatinib, pertuzumab, trastuzumab emtansine and neratinib...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29739384/menos4-trial-a-multicentre-randomised-controlled-trial-rct-of-a-breast-care-nurse-delivered-cognitive-behavioural-therapy-cbt-intervention-to-reduce-the-impact-of-hot-flushes-in-women-with-breast-cancer-study-protocol
#19
Deborah Fenlon, Jacqueline Nuttall, Carl May, James Raftery, Jo Fields, Emma Kirkpatrick, Julia Abab, Mary Ellis, Taylor Rose, Priya Khambhaita, Angeliki Galanopoulou, Tom Maishman, Jo Haviland, Gareth Griffiths, Lesley Turner, Myra Hunter
BACKGROUND: Women who have been treated for breast cancer may identify vasomotor symptoms, such as hot flushes and night sweats (HFNS), as a serious problem. HFNS are unpleasant to experience and can have a significant impact on daily life, potentially leading to reduced adherence to life saving adjuvant hormonal therapy. It is known that Cognitive Behavioural Therapy (CBT) is effective for the alleviation of hot flushes in both well women and women who have had breast cancer. Most women with breast cancer will see a breast care nurse and there is evidence that nurses can be trained to deliver psychological treatments to a satisfactory level, whilst also maintaining treatment fidelity...
May 8, 2018: BMC Women's Health
https://www.readbyqxmd.com/read/29737474/incidence-and-risk-factors-for-congestive-heart-failure-in-patients-with-early-breast-cancer-who-received-anthracycline-and-or-trastuzumab-a-big-data-analysis-of-the-korean-health-insurance-review-and-assessment-service-database
#20
Jung Yoon Choi, Eun Young Cho, Yoon Ji Choi, Jeong Hyeon Lee, Seung Pil Jung, Kyu Ran Cho, Chul Yong Kim, Yeul Hong Kim, Kyong Hwa Park
PURPOSE: We aimed to analyze the incidence, time to occurrence, and congestive heart failure (CHF) risk factors for early breast cancer patients treated with anthracycline (AC)-based chemotherapy and/or trastuzumab (T) therapy in Korea. METHODS: We included female patients > 19 years old from the Health Insurance Review and Assessment Service database who had no prior CHF history and had been diagnosed with early breast cancer between January 2007 and October 2016...
May 8, 2018: Breast Cancer Research and Treatment
keyword
keyword
118674
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"